EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells

Cell Cycle

Volumn 12, Issue 18, 2013, Pages 2978-2991

  Lainey, Elodie ^a,b,c,d   Wolfromm, Alice ^a,b,e   Sukkurwala, Abdul Qader ^a,b,c   Micol, Jean Baptiste ^b   Fenaux, Pierre ^a,f   Galluzzi, Lorenzo ^b,e,g   Kepp, Oliver ^a,b,g   Kroemer, Guido ^a,b,f,h  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f AVICENNE HOSPITAL   (France)

^g CENTRE DE RECHERCHE DES CORDELIERS   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

BCR ABL; Cancer; Dasatinib; Imatinib; Monocyte specific esterase; PML RAR

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; COLECALCIFEROL; ERLOTINIB; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN TYROSINE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL AGING; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LEUKEMIA CELL;

ATRA;

BCR-ABL; CANCER; DASATINIB; IMATINIB; MONOCYTE-SPECIFIC ESTERASE; PML-RARΑ;

ANTIGENS, CD11B; ANTIGENS, CD34; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CHOLECALCIFEROL; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOGEN-ACTIVATED PROTEIN KINASE 14; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 84884869442     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26016     Document Type: Article

References (64)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
2. Pandolfi A, Barreyro L, Steidl U. Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Transl Med 2013; 2:143-50; PMID:23349328; http://dx.doi.org/ 10.5966/sctm.2012-0109
3. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; 9:447-64; PMID:20467424; http://dx.doi.org/ 10.1038/nrd3137
4. Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009; 16:84-91; PMID:19468269; http://dx.doi.org/10.1097/MOH.0b013e3283257aee
5. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood 2009; 113:3655-65; PMID:19221035; http://dx.doi.org/10.1182/blood-2009-01-198911
6. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29:487-94; PMID:21220605; http://dx.doi.org/10.1200/JCO.2010.30.1820
7. Hughes PJ, Marcinkowska E, Gocek E, Studzinski GP, Brown G. Vitamin D3-driven signals for myeloid cell differentiation - implications for differentiation therapy. Leuk Res 2010; 34:553-65; PMID:19811822; http://dx.doi.org/10.1016/j.leukres.2009.09.010
8. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7:684-700; PMID:17721433; http://dx.doi.org/10.1038/nrc2196
9. Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J 2010; 16:1-9; PMID:20164683; http://dx.doi.org/10.1097/PPO.0b013e3181c51ee6
10. Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, Wong M, Johnson C, Trump DL. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer 2010; 116:2132-9; PMID:20166215
11. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013; 88:318-27; PMID:23526416; http://dx.doi.org/10. 1002/ajh.23404
12. Visser O, Trama A, Maynadié M, Stiller C, Marcos- Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, et al.; RARECARE Working Group. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012; 48:3257-66; PMID:22770878; http://dx.doi.org/10.1016/j.ejca. 2012.05.024
13. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, Preudhomme C. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008; 22:915-31; PMID:18288131; http://dx.doi.org/10. 1038/leu.2008.19
14. Fröhling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005; 23:6285-95; PMID:16155011; http://dx.doi.org/10.1200/JCO.2005.05.010
15. Roboz GJ. Current treatment of acute myeloid leukemia. Curr Opin Oncol 2012; 24:711-9; PMID:23014187; http://dx.doi.org/10.1097/CCO.0b013e328358f62d
16. Yanada M, Naoe T. Acute myeloid leukemia in older adults. Int J Hematol 2012; 96:186-93; PMID:22791510; http://dx.doi.org/10.1007/s12185-012-1137-3
17. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol 2011; 152:524-42; PMID:21314823; http://dx.doi.org/10.1111/j.1365-2141.2010.08470.x
18. Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, et al.; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361:1235-48; PMID:19776405; http://dx.doi.org/10. 1056/NEJMoa0901409
19. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, Pelicci PG, Miller WH Jr. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 1996; 88:2826-32; PMID:8874178
20. Lindhagen E, Eriksson A, Wickström M, Danielsson K, Grundmark B, Henriksson R, Nygren P, Aleskog A, Larsson R, Höglund M. Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur J Haematol 2008; 81:344-53; PMID:18637032
21. Boehrer S, Adès L, Galluzzi L, Tajeddine N, Tailler M, Gardin C, de Botton S, Fenaux P, Kroemer G. Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. Biochem Pharmacol 2008; 76:1417-25; PMID:18617157; http://dx.doi.org/10.1016/j. bcp.2008.05.024
22. Pitini V, Arrigo C, Altavilla G. Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J Clin Oncol 2008; 26:3645-6; PMID:18640945; http://dx.doi.org/10.1200/JCO.2008.17.0357
23. Chan G, Pilichowska M. Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood 2007; 110:1079-80; PMID:17644748; http://dx.doi.org/10.1182/blood-2007-01- 069856
24. Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008; 111:2170-80; PMID:17925489; http://dx.doi.org/10.1182/blood-2007-07-100362
25. Sun JZ, Lu Y, Xu Y, Liu F, Li FQ, Wang QL, Wu CT, Hu XW, Duan HF. Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis. Hematol Oncol 2012; 30:89-97; PMID:22674781; http://dx.doi.org/10.1002/hon.1002
26. Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR, Golub TR. Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet 2004; 36:257-63; PMID:14770183; http://dx.doi.org/10.1038/ng1305
27. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 2005; 106:2841-8; PMID:15998836; http://dx.doi.org/10.1182/blood-2005-02-0488
28. Kansas GS, Muirhead MJ, Dailey MO. Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. Blood 1990; 76:2483-92; PMID:1702327
29. Lainey E, Thépot S, Bouteloup C, Sébert M, Adès L, Tailler M, Gardin C, de Botton S, Baruchel A, Fenaux P, et al. Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action. Biochem Pharmacol 2011; 82:1457-66; PMID:21664897; http://dx.doi.org/10.1016/j.bcp.2011.05.011
30. Breitman TR, Hemmi H, Imaizumi M. Induction by physiological agents of differentiation of the human leukemia cell line HL-60 to cells with functional characteristics. Prog Clin Biol Res 1986; 226:215-33; PMID:3543956
31. Sokol RJ, Hudson G, Wales JM, Goldstein DJ, James NT. Quantitative enzyme cytochemistry during human macrophage development. J Anat 1993; 183:97-101; PMID:8270480
32. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, et al.; Nomenclature Committee on Cell Death 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16:3-11; PMID:18846107; http://dx.doi.org/10.1038/cdd.2008.150
33. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19:107-20; PMID:21760595; http://dx.doi.org/10.1038/cdd.2011.96
34. Vitale I, Jemaà M, Galluzzi L, Metivier D, Castedo M, Kroemer G. Cytofluorometric assessment of cell cycle progression. Methods Mol Biol 2013; 965:93-120; PMID:23296653; http://dx.doi.org/10.1007/978-1-62703-239-1-6
35. Boehrer S, Adès L, Tajeddine N, Hofmann WK, Kriener S, Bug G, Ottmann OG, Ruthardt M, Galluzzi L, Fouassier C, et al. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene 2009; 28:2205-18; PMID:19398952; http://dx.doi.org/10.1038/onc.2009.69
36. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10:221-37; PMID:21358741; http://dx.doi.org/10.1038/nrd3373
37. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009; 16:1093-107; PMID:19373242; http://dx.doi.org/10.1038/ cdd.2009.44
38. Zhang T, He YM, Wang JS, Shen J, Xing YY, Xi T. Ursolic acid induces HL60 monocytic differentiation and upregulates C/EBPβ expression by ERK pathway activation. Anticancer Drugs 2011; 22:158-65; PMID:20948428; http://dx.doi.org/10.1097/CAD.0b013e3283409673
39. Yen A, Roberson MS, Varvayanis S, Lee AT. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinasedependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 1998; 58:3163-72; PMID:9679985
40. Zhang J, Harrison JS, Studzinski GP. Isoforms of p38MAPK gamma and delta contribute to differentiation of human AML cells induced by 1,25- dihydroxyvitamin D. Exp Cell Res 2011; 317:117-30; PMID:20804750; http://dx.doi.org/10.1016/j.yexcr.2010.08.010
41. Congleton J, MacDonald R, Yen A. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPKdependent differentiation of myeloid leukemia cells. Leukemia 2012; 26:1180-8; PMID:22182854; http://dx.doi.org/10.1038/leu.2011.390
42. Gothot A, Pyatt R, McMahel J, Rice S, Srour EF. Functional heterogeneity of human CD34(+) cells isolated in subcompartments of the G0 /G1 phase of the cell cycle. Blood 1997; 90:4384-93; PMID:9373249
43. Itahana K, Campisi J, Dimri GP. Methods to detect biomarkers of cellular senescence: the senescenceassociated beta-galactosidase assay. Methods Mol Biol 2007; 371:21-31; PMID:17634571; http://dx.doi.org/10.1007/978-1-59745-361-5-3
44. Miranda MB, Redner RL, Johnson DE. Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation. Mol Cancer Ther 2007; 6:3081-90; PMID:18065491; http://dx.doi.org/10.1158/1535-7163. MCT-07-0514
45. Noh EK, Kim H, Park MJ, Baek JH, Park JH, Cha SJ, Won JH, Min YJ. Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line. Leuk Res 2010; 34:1501-5; PMID:20226526; http://dx.doi.org/10.1016/j.leukres.2010.02.016
46. Jensen HA, Styskal LE, Tasseff R, Bunaciu RP, Congleton J, Varner JD, Yen A. The Src-family kinase inhibitor PP2 rescues inducible differentiation events in emergent retinoic acid-resistant myeloblastic leukemia cells. PLoS One 2013; 8:e58621; PMID:23554907; http://dx.doi.org/10.1371/journal. pone.0058621
47. Weber C, Schreiber TB, Daub H. Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 2012; 75:1343-56; PMID:22115753; http://dx.doi.org/10.1016/j.jprot.2011.11.004
48. Boehrer S, Galluzzi L, Lainey E, Bouteloup C, Tailler M, Harper F, Pierron G, Adès L, Thépot S, Sébert M, et al. Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle 2011; 10:3168-75; PMID:21897118; http://dx.doi.org/10.4161/cc.10.18.16599
49. Jones JE, Wang L, Kropf PL, Duan R, Johnson DE. Src family kinase gene targets during myeloid differentiation: identification of the EGR-1 gene as a direct target. Leukemia 2009; 23:1933-5; PMID:19494839; http://dx.doi.org/10. 1038/leu.2009.118
50. Stabile LP, He G, Lui VW, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res 2013; 19:380-92; PMID:23213056; http://dx.doi.org/10.1158/1078-0432.CCR-12-1555
51. Huang HL, Chen YC, Huang YC, Yang KC, Pan Hy, Shih SP, Chen YJ. Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells. PLoS One 2011; 6:e29014; PMID:22216158; http://dx.doi.org/10.1371/journal.pone.0029014
52. Quintás-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond - exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009; 6:535-43; PMID:19652654; http://dx.doi.org/10.1038/nrclinonc.2009.112
53. Kropf PL, Wang L, Zang Y, Redner RL, Johnson DE. Dasatinib promotes ATRA-induced differentiation of AML cells. Leukemia 2010; 24:663-5; PMID:20033056; http://dx.doi.org/10.1038/leu.2009.267
54. Chevalier N, Solari ML, Becker H, Pantic M, Gärtner F, Maul-Pavicic A, Hübner J, Wäsch R, Schmitt-Gräff A, Lübbert M. Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib. Leukemia 2010; 24:1779-81; PMID:20811401; http://dx.doi.org/10.1038/leu.2010.151
55. Fedorov O, Müller S, Knapp S. The (un)targeted cancer kinome. Nat Chem Biol 2010; 6:166-9; PMID:20154661; http://dx.doi.org/10.1038/nchembio.297
56. ten Hacken E, Scielzo C, Bertilaccio MT, Scarfò L, Apollonio B, Barbaglio F, Stamatopoulos K, Ponzoni M, Ghia P, Caligaris-Cappio F. Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. Blood 2013; 121:2264-73; PMID:23325840; http://dx.doi.org/10.1182/blood-2012-09-457119
57. Lainey E, Wolfromm A, Marie N, Enot D, Scoazec M, Bouteloup C, Leroy C, Micol JB, De Botton S, Galluzzi L, et al. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene 2012; In press; PMID:23085751; http://dx.doi.org/10.1038/onc.2012.469.
58. Lainey E, Sébert M, Thépot S, Scoazec M, Bouteloup C, Leroy C, De Botton S, Galluzzi L, Fenaux P, Kroemer G. Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle 2012; 11:4079-92; PMID:23095522; http://dx.doi.org/10.4161/cc.22382
59. Collins SJ, Bodner A, Ting R, Gallo RC. Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by componuds which induce differentiation of murine leukemia cells. Int J Cancer 1980; 25:213-8; PMID:6156128; http://dx.doi.org/10.1002/ijc.2910250208
60. Jemaà M, Galluzzi L, Kepp O, Castedo M, Rello- Varona S, Vitale I, Kroemer G. Transgenerational cell fate profiling: a method for the graphical presentation of complex cell cycle alterations. Cell Cycle 2013; 12:183-90; PMID:23255111; http://dx.doi.org/10.4161/cc.23046
61. Vitale I, Galluzzi L, Vivet S, Nanty L, Dessen P, Senovilla L, Olaussen KA, Lazar V, Prudhomme M, Golsteyn RM, et al. Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. PLoS One 2007; 2:e1337; PMID:18159231; http://dx.doi.org/10.1371/journal.pone.0001337
62. Galluzzi L, Marsili S, Vitale I, Senovilla L, Michels J, Garcia P, Vacchelli E, Chatelut E, Castedo M, Kroemer G. Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle 2013; 12:417-21; PMID:23287530; http://dx.doi.org/10.4161/cc.23275
63. Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012; 2:257-69; PMID:22854025; http://dx.doi.org/10.1016/j.celrep.2012.06.017
64. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in nonsmall cell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67:6253-62; PMID:17616683; http://dx.doi.org/10.1158/0008-5472.CAN-07-0538